Zoetis Inc. (NYSE:ZTS) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $2.34-$2.39 for the period, compared to the Thomson Reuters consensus estimate of $2.34. The company issued revenue guidance of $5.225-$5.275 billion, compared to the consensus revenue estimate of $5.20 billion.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.03. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.52 EPS.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a $0.105 dividend. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 annualized dividend and a dividend yield of 0.66%. Zoetis’s payout ratio is currently 23.73%.

Several analysts recently weighed in on ZTS shares. Cowen and Company set a $60.00 price target on Zoetis and gave the stock a buy rating in a research note on Tuesday, July 11th. Deutsche Bank AG restated a buy rating and issued a $65.00 price target (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Stifel Nicolaus restated a buy rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, July 21st. Goldman Sachs Group, Inc. (The) restated a neutral rating and issued a $62.00 price target on shares of Zoetis in a research note on Monday, August 7th. Finally, Cantor Fitzgerald set a $75.00 price target on Zoetis and gave the stock a buy rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $65.76.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/zoetis-inc-zts-releases-fy17-earnings-guidance.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.